PET Imaging of Estrogen Receptors Using 18F-Based Radioligands.
Sign Up to like & getrecommendations! Published in 2022 at "Methods in molecular biology"
DOI: 10.1007/978-1-0716-1920-9_9
Abstract: In vivo molecular imaging of estrogen receptor alpha (ER) can be performed via positron emission tomography (PET) using ER-specific radioligands, such as 16α-[18F]fluoro-17β-estradiol (18F-FES). 18F-FES is a radiopharmaceutical recently approved by the United States Food… read more here.
Keywords: fes pet; pet imaging; imaging estrogen; 18f fes ... See more keywords
Discrepancy between [18F]-FES and [18F]-FDG PET/CT in ER-positive breast cancer with oesophageal metastasis
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-022-05759-z
Abstract: A 79-year-old woman with recurrent invasive lobular carcinoma (ILC) of the right breast underwent right mastectomy with right axillary node dissection, radiotherapy at the right chest wall, and letrozole. She presented with progressive dysphagia and… read more here.
Keywords: breast; 18f fdg; chest wall; 18f fes ... See more keywords
Update on 18F-Fluoroestradiol.
Sign Up to like & getrecommendations! Published in 2024 at "Seminars in nuclear medicine"
DOI: 10.1053/j.semnuclmed.2024.09.001
Abstract: 18F-16α-Fluoroestradiol (18F-FES) is a radiolabeled estrogen analogue positron emission tomography (PET) imaging agent that binds to the estrogen receptor (ER) in the nucleus of ER-expressing cells. Proof-of-concept studies of 18F-FES demonstrated expected correlation between tumoral… read more here.
Keywords: breast cancer; fes pet; 18f fluoroestradiol; 18f fes ... See more keywords
18F-FES PET/CT for Characterization of Brain and Leptomeningeal Metastasis in Double Primary Cancer Patient.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000004197
Abstract: ABSTRACT The clinical value of 16α-18F-fluoro-17 β-estradiol (18F-FES) PET in breast cancer has been widely investigated because it can visualize estrogen receptor-expressing lesions. This relatively new radiotracer adds clinical values by characterization of metastasis in… read more here.
Keywords: 18f fes; fes pet; brain; metastasis double ... See more keywords
Collagen Vascular Disease-Associated Interstitial Pneumonia With Accumulation of 18F-fluoroestradiol.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000005743
Abstract: 18F-fluoroestradiol (18F-FES) is a PET radiotracer that binds to the estrogen receptor (ER) in the nucleus of ER-expressing cells and is increasingly used clinically in breast cancer patients to visualize ER expression in lesions. Although… read more here.
Keywords: collagen vascular; accumulation; vascular disease; 18f fluoroestradiol ... See more keywords
Abstract PO2-07-07: The role of PET imaging with [18F]16α-fluoro-17β-fluoroestradiol in predicting response to endocrine therapies in patients with breast cancer
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-po2-07-07
Abstract: Background Fluoroestradiol F18 is a radioactive diagnostic agent (18F-FES) used with positron emission tomography (PET) imaging to detect estrogen-receptor (ER)-positive lesions in patients with breast cancer. Convened by the Society of Nuclear Medicine and Molecular… read more here.
Keywords: fes; response; 18f fes; endocrine therapies ... See more keywords
Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00400
Abstract: PURPOSE Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α-[18F]fluoro-17β-estradiol positron emission tomography ([18F]FES-PET) is increasingly used for this purpose. To establish the clinical validity… read more here.
Keywords: metastasis; 18f fes; fes pet; status ... See more keywords
The clinical value of 18F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies.
Sign Up to like & getrecommendations! Published in 2021 at "Quantitative imaging in medicine and surgery"
DOI: 10.21037/qims-20-1364
Abstract: Background For patients with previously diagnosed dual primary tumors, it is usually difficult to determine the diagnosis and treatment of stage IV recurrence. The study was to explore the influences of 18F-fluoroestradiol positron emission tomography/computed… read more here.
Keywords: fes pet; treatment; dual primary; 18f fluoroestradiol ... See more keywords
ZR-75-1 breast cancer models to study the utility of 18F-FES by PET imaging
Sign Up to like & getrecommendations! Published in 2021 at "Translational Cancer Research"
DOI: 10.21037/tcr-20-3228
Abstract: Background Breast cancer is a hormone-dependent tumor, and 70–80% of breast cancer patients are estrogen receptor (ER) positive. ZR-75-1 cell lines are more consistent with human breast cancer, which is mostly ER positive and PR… read more here.
Keywords: cancer; tumor; breast cancer; 18f fes ... See more keywords
Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.580277
Abstract: Objective The purpose of this study was to employ dual tracers 16α-[18F]fluoro-17β-estradiol (18F-FES) and [18F]fluorodeoxyglucose (18F-FDG) as imaging biomarkers in predicting progression-free survival (PFS) in ER-positive metastatic breast cancer (MBC) patients receiving fulvestrant therapy. Methods… read more here.
Keywords: 18f fes; fes fdg; fulvestrant therapy;
Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18F-FES PET
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14143531
Abstract: Simple Summary About 10–20% of breast cancer patients have a heterogeneous estrogen receptor expression. The diagnosis and treatment strategy remains controversial in these patients, especially regarding the metastatic pattern. The aim of our study was… read more here.
Keywords: breast cancer; estrogen receptor; fes pet; 18f fes ... See more keywords